Stevens–Johnson syndrome seems to occur as a response to several different drugs, but apparently only to people with a specific HLA genotype. Part of the solution here is that currently we only approve a drug if it is safe for nearly 100% of the population, even if it is useful for far fewer (see statins) and the path forward needs to give more consideration of the differences in people, and having suitable genotyping a prerequisite for some medications.